What was a notable safety finding in the MajesTEC-3 trial regarding the teclistamab-daratumumab arm?
Higher rate of cytokine release syndrome throughout the study
More serious/fatal infections, mostly during the first 6 months before broader infection mitigation strategies
Increased cardiovascular toxicity compared to triplet therapy